Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services
Diversified Medical Healthcare Acquires Utah Lab, Dynasty Medical Laboratory Services […]
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes […]
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors […]
PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update
SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021. Recent Business and Financial Updates In the first quarter of 2022, PolarityTE received approval from the U.S. […]
Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital
The total capital represents the largest seed financing for life science startups in Utah’s history […]
Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s Disease
Halia Therapeutics presented data today on its NLRP3 inhibitor program at today’s 10th Annual Neurodegenerative Drug Development Summit. […]
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022 […]
MDUFA V Agreement Reached
The FDA and representatives from the medical device industry have reached an agreement on proposed recommendations for MDUFA V. On March 22, FDA sent the commitment letter to Congress. Under the new agreement, the FDA would be authorized to collect at least $1.78 billion in user fees over five years. FDA could receive additional funding […]
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arena
Pfizer’s $6.7 billion bet on Arena Pharmaceuticals has delivered a phase 3 success. […]
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
Recursion reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021. […]
FierceBiotech recognizes Recursion as the #2 Biotech IPO of 2021!
FierceBiotech Special Report: The top 10 biotech IPOs of 2021 […]
Co-Diagnostics Reports Full Year 2021 Financial Results
Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY’22 […]